• Beta-adrenergic signaling is altered in denervated hearts following transplantation, evidenced by heightened isoprenaline responsiveness, possible receptor supersensitivity, and shifts in myocardial catecholamine content, suggesting presynaptic alterations and sustained adrenergic tone changes [1], [3], [18].

• Immunosuppressive regimens and targeted immune-modulation were repeatedly tested to extend xenograft survival, including total lymphoid irradiation, cyclosporine A, 15-deoxyspergualin, and monoclonal antibodies, with examples in hamster-to-rat and primate models indicating delayed rejection and survival extensions [10], [16], [19], [14], [15].

• A core pattern centers on developing robust cross-species heart transplantation models and preservation techniques, including cold storage of rat hearts, modified Wisconsin solution for heart preservation, and heterotopic rat heart transplants to study viability and atrophy, informing xenograft feasibility [2], [7], [6].

• Pathophysiology of rejection shows both allo- and xenograft patterns, with early mechanisms of discordant xenograft rejection, sequential morphologic analyses revealing distinct pathways, and emphasis on vascular/humoral contributions in graft failure [9], [13], [20], [14].

• Advances in diagnostic assays for xenograft rejection include flow cytometric detection of cytotoxic antibodies and histopathologic monitoring, enabling more precise tracking of humoral and cellular responses in hamster-to-rat models and beyond [17], [13], [20].